Published in Neurology on February 28, 2006
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol (2010) 3.32
100 years and counting: prospects for defeating Alzheimer's disease. Science (2006) 3.24
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood (2008) 1.69
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics (2008) 1.55
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov (2013) 1.47
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One (2010) 1.41
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia (2007) 1.29
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis (2009) 1.10
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci (2010) 1.09
ACS chemical neuroscience molecule spotlight on semagacestat (LY450139). ACS Chem Neurosci (2010) 1.09
Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr Alzheimer Res (2008) 1.09
Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol (2010) 1.07
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener (2009) 1.07
Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol (2008) 1.03
Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord (2011) 1.03
Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta (2008) 1.01
Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother (2010) 0.99
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs (2012) 0.97
Notch signaling as a novel regulator of metabolism. Trends Endocrinol Metab (2015) 0.95
Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Mol Brain (2008) 0.94
Mature human eosinophils express functional Notch ligands mediating eosinophil autocrine regulation. Blood (2009) 0.94
Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther (2010) 0.91
Progress in Alzheimer's disease. J Neurol (2011) 0.90
A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity. PLoS One (2009) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimers Res Ther (2012) 0.87
At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.86
Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther (2014) 0.85
Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem (2012) 0.85
Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med (2009) 0.84
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther (2015) 0.83
Mutations in nicastrin protein differentially affect amyloid beta-peptide production and Notch protein processing. J Biol Chem (2011) 0.82
Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxid Med Cell Longev (2015) 0.81
RBPJ is a novel target for rhabdomyosarcoma therapy. PLoS One (2012) 0.81
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther (2015) 0.80
Amyloid-β and APP deficiencies cause severe cerebrovascular defects: important work for an old villain. PLoS One (2013) 0.80
Brain amyloid β protein and memory disruption in Alzheimer's disease. Neuropsychiatr Dis Treat (2010) 0.80
Mechanism-based treatments for Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.80
Translational research in neurology: dementia. Arch Neurol (2012) 0.79
Chronic administration of anti-stroke herbal medicine TongLuoJiuNao reduces amyloidogenic processing of amyloid precursor protein in a mouse model of Alzheimer's disease. PLoS One (2013) 0.79
Current therapeutic options for Alzheimer's disease. Curr Genomics (2007) 0.79
Tarenflurbil: mechanisms and myths. Arch Neurol (2010) 0.78
Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. J Neuropathol Exp Neurol (2012) 0.78
gamma-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranes. PLoS One (2010) 0.78
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. Age (Dordr) (2010) 0.77
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges. J Clin Neurol (2016) 0.76
New computer-aided diagnosis of dementia using positron emission tomography: brain regional sensitivity-mapping method. PLoS One (2011) 0.76
Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics. Curr Transl Geriatr Exp Gerontol Rep (2013) 0.76
Inhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo. Exp Eye Res (2014) 0.75
In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects. Int J Alzheimers Dis (2013) 0.75
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug Discov Today (2016) 0.75
Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer. Oncotarget (2016) 0.75
Biomarkers for Alzheimer's disease: showing the way or leading us astray? J Alzheimers Dis (2013) 0.75
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? Open Neurol J (2009) 0.75
Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease? J Alzheimers Parkinsonism Dement (2016) 0.75
Global analysis of protein activities using proteome chips. Science (2001) 13.74
Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 7.27
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA (1994) 5.98
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol (1992) 5.18
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Cognitive impairment in hemodialysis patients is common. Neurology (2006) 3.68
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology (2005) 3.21
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry (2001) 3.09
Rodletless, a new Aspergillus developmental mutant induced by directed gene inactivation. Genes Dev (1991) 3.04
Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex. Neuron (2000) 3.03
The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology (2012) 3.01
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A (1977) 2.90
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Reactivity of monoclonal antibodies to Rickettsia rickettsii with spotted fever and typhus group rickettsiae. J Clin Microbiol (1987) 2.86
Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology (2003) 2.85
Rice transposable elements: a survey of 73,000 sequence-tagged-connectors. Genome Res (2000) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology (2009) 2.74
Motor slowing precedes cognitive impairment in the oldest old. Neurology (1998) 2.74
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A (1992) 2.64
Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest (1998) 2.64
Trajectories of brain loss in aging and the development of cognitive impairment. Neurology (2007) 2.60
The adenylate cyclase gene MAC1 of Magnaporthe grisea controls appressorium formation and other aspects of growth and development. Plant Cell (1997) 2.59
Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology (2011) 2.52
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
The cAMP-dependent protein kinase catalytic subunit is required for appressorium formation and pathogenesis by the rice blast pathogen Magnaporthe grisea. Plant Cell (1995) 2.46
Reporting potential bias: Neurology's evolving policies. Neurology (2011) 2.46
Voluntary regionalization and associated trends in perinatal care: the Nova Scotia Reproductive Care Program. Am J Obstet Gynecol (1983) 2.45
Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology (2008) 2.45
1H MR spectroscopy in common dementias. Neurology (2004) 2.39
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol (1997) 2.32
In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc Natl Acad Sci U S A (1999) 2.24
BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci (2000) 2.22
Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med (2001) 2.21
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol (2007) 2.18
G protein alpha subunit genes control growth, development, and pathogenicity of Magnaporthe grisea. Mol Plant Microbe Interact (1997) 2.17
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology (2000) 2.10
Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol (1997) 2.07
Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology (1998) 2.07
A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events. EMBO J (1998) 2.05
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Hemoglobin concentration of high-altitude Tibetans and Bolivian Aymara. Am J Phys Anthropol (1998) 1.99
Wave energy and intertidal productivity. Proc Natl Acad Sci U S A (1987) 1.99
Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem (2001) 1.98
Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology (2003) 1.97
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology (2010) 1.93
Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol (1994) 1.92
A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology (2008) 1.91
Diffusion tensor imaging and cognitive function in older adults with no dementia. Neurology (2011) 1.89
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology (2009) 1.85
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology (2011) 1.84
Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther (1996) 1.81
Impaired synaptic plasticity and cAMP response element-binding protein activation in Ca2+/calmodulin-dependent protein kinase type IV/Gr-deficient mice. J Neurosci (2000) 1.81
Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Neurology (1997) 1.81
Assessing the privacy risks of data sharing in genomics. Public Health Genomics (2010) 1.78
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology (2011) 1.75
Amyloid protein of Gerstmann-Sträussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. EMBO J (1991) 1.74
Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Neurol (2011) 1.74
Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol (1988) 1.73
Ethanol-induced neuronal apoptosis in vivo requires BAX in the developing mouse brain. Cell Death Differ (2003) 1.72
Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci (2000) 1.72
Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A (1979) 1.72
Imaging correlates of pathology in corticobasal syndrome. Neurology (2010) 1.71
Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J Neurochem (1996) 1.70
Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology (2011) 1.70
Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry (2003) 1.70
Amyloid fibrils in Gerstmann-Sträussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell (1994) 1.69
Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem (1997) 1.67
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nat Genet (1992) 1.66
In vivo and in vitro clonal deletion of double-positive thymocytes. J Exp Med (1992) 1.66
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology (2010) 1.66
Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell (1989) 1.66
Prion protein amyloidosis. Brain Pathol (1996) 1.64
Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem (1999) 1.64
Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology (2008) 1.62